Drug
Tislelizumab Fruquintinib
Tislelizumab Fruquintinib: highest development phase Phase 2, developed by Hutchmed. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Hutchmed
Trials
| Drug | Phase | Indication |
|---|---|---|
| Tislelizumab & Fruquintinib NCT05690035 | Phase 2 | Metastatic Colorectal Cancer |
Latest
No recent events.
Follow Tislelizumab Fruquintinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.